Abstract
Forty patients with acute laryngopharyngitis were administered Rinderon-containing nebulizer therapy in a study designed to evaluate the optimum dosage, efficacy, and side effects of this corticosteroid. A significantly greater number of patients responded favorably to this medication administered in dose concentrations of 1.5mg than patients treated with lower dose concentrations of the drug. Inpatients who received Rinderon-containing nebulizer therapy in doses of 1.5mg for several days demonstrated normal plasma cortisol levels after seven days of such treatment. Results of outpatient studies involving forty patients treated every other day with 1.5mg doses of Rinderon-containing nebulizer therapy indicated that such therapy is more efficacious and elicits fewer side effects than other treatment modalities.
